Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | FPR1 | P21462 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | C1S | P09871 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610736 | 0.96 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3395754 | 0.94 | MAPK1 (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8003695 | 0.91 | — | — | |
| SCHEMBL22448993 | 0.86 | ALDH1A1 (0.41) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8256801 | 0.84 | MAPT (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22860589 | 0.82 | HRH4 (0.42) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10194544 | 0.82 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2671753 | 0.82 | RAB9A (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2583255 | 0.77 | ADORA1 (0.46) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2583252 | 0.77 | ADORA1 (0.46) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020002090-A1 | SUBSTITUTED THIAZOLYLPYRROLONES, SALTS THEREOF AND THE USE THEREOF AS HERBICIDAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-02 | — | — | WO | disclosed |
| WO-2012020022-A1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| EP-0999209-B1 | 2-SULFAMOYLBENZOIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | KAKEN PHARMACEUTICALS | 2002-04-25 | — | — | US | disclosed |
| US-6376671-B1 | LEUKOTRIENE AND THROMBOXANE A2 ANTAGONISTIC AGENTS; ANTIALLERGIC AGENTS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6255321-B1 | ANTIALLERGENS; RESPIRATRORY SYSTEM DISORDERS | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | disclosed |
| EP-0999209-A1 | 2-SULFAMOYLBENZOIC ACID DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2000-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | RAB9A 2342/4885NPC1 322/4885SMN1; SMN2 2582/4885 |
| US-20020049228-A1 | 2-Sulfamoylbenzoic acid derivatives | LTB4R2, LTB4R, CYSLTR2 | RAB9A 3630/4885NPC1 4511/4885SMN1; SMN2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.